- Home
- EMO vs PHAR Comparison
EMO vs PHAR Comparison
Compare EMO & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMO
- PHAR
- Stock Information
- Founded
- EMO 2011
- PHAR 1988
- Country
- EMO United States
- PHAR Netherlands
- Employees
- EMO N/A
- PHAR N/A
- Industry
- EMO Investment Managers
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- EMO Finance
- PHAR Health Care
- Exchange
- EMO Nasdaq
- PHAR Nasdaq
- Market Cap
- EMO 848.0M
- PHAR 718.1M
- IPO Year
- EMO N/A
- PHAR N/A
- Fundamental
- Price
- EMO $46.23
- PHAR $11.24
- Analyst Decision
- EMO
- PHAR Strong Buy
- Analyst Count
- EMO 0
- PHAR 3
- Target Price
- EMO N/A
- PHAR $30.00
- AVG Volume (30 Days)
- EMO 27.1K
- PHAR 3.2K
- Earning Date
- EMO 01-01-0001
- PHAR 05-08-2025
- Dividend Yield
- EMO 6.70%
- PHAR N/A
- EPS Growth
- EMO N/A
- PHAR N/A
- EPS
- EMO N/A
- PHAR N/A
- Revenue
- EMO N/A
- PHAR $320,708,000.00
- Revenue This Year
- EMO N/A
- PHAR $13.31
- Revenue Next Year
- EMO N/A
- PHAR $7.68
- P/E Ratio
- EMO N/A
- PHAR N/A
- Revenue Growth
- EMO N/A
- PHAR 24.13
- 52 Week Low
- EMO $26.42
- PHAR $6.65
- 52 Week High
- EMO $40.17
- PHAR $11.72
- Technical
- Relative Strength Index (RSI)
- EMO 52.14
- PHAR 67.56
- Support Level
- EMO $45.12
- PHAR $10.02
- Resistance Level
- EMO $46.42
- PHAR $10.89
- Average True Range (ATR)
- EMO 1.05
- PHAR 0.26
- MACD
- EMO 0.01
- PHAR 0.09
- Stochastic Oscillator
- EMO 49.69
- PHAR 84.08
About EMO ClearBridge Energy Midstream Opportunity Fund Inc.
ClearBridge Energy Midstream Opportunity Fund Inc is a non-diversified, closed-end management investment company. Its investment objective is to provide long-term investors with a high level of total return with an emphasis on cash distributions. The Fund considers investments in midstream entities as those entities that provide midstream services including the gathering, transporting, processing, fractionation, storing, refining, and distribution of oil, natural gas liquids and natural gas.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.